Wang Meibin, Fu Yujie, Zhong Chuyue, Gacche Rajesh N, Wu Peiliang
The Dingli Clinical college of Wenzhou Medical University, Wenzhou 325000, PR China.
Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, PR China.
Heliyon. 2023 Nov 24;9(12):e22591. doi: 10.1016/j.heliyon.2023.e22591. eCollection 2023 Dec.
Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with a high incidence and mortality rates of all cancers. Locally advanced or metastatic NSCLC patients can benefit from platinum-based chemotherapy and targeted therapy drugs. Nevertheless, primary or acquired drug resistance will result in ineffective treatment, leading to tumor progression. The detailed mechanism underlying drug resistance to NSCLC are complicated and result from various factor. Among them, long noncoding RNAs (lncRNAs) have been found to be critically involved in NSCLC development and play a vital role in mediating therapy resistance. In this review, we attempt to systematically summarize the mechanisms underlying the lncRNA-mediated resistance to chemotherapy agents and targeted therapy drugs against lung cancer.
非小细胞肺癌（NSCLC）是最具毁灭性的癌症之一，在所有癌症中发病率和死亡率都很高。局部晚期或转移性NSCLC患者可从铂类化疗和靶向治疗药物中获益。然而，原发性或获得性耐药会导致治疗无效，从而导致肿瘤进展。NSCLC耐药的详细机制很复杂，是由多种因素造成的。其中，长链非编码RNA（lncRNA）已被发现与NSCLC的发展密切相关，并在介导治疗耐药中发挥重要作用。在这篇综述中，我们试图系统地总结lncRNA介导的肺癌化疗药物和靶向治疗药物耐药的机制。
